52 results
8-K
EX-99.1
ARVN
Arvinas Inc
7 May 24
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:02am
or metastatic breast cancer.
Received U.S. Food and Drug Administration Fast Track designation for the investigation of vepdegestrant for monotherapy … .
Vepdegestrant has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the investigation of vepdegestrant for monotherapy
8-K
EX-99.1
ARVN
Arvinas Inc
27 Feb 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:02am
for the investigation of vepdegestrant for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth
8-K
EX-10.1
l6mdlqonfw nuap
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
8-K
EX-4.1
hrrjry ds60u37w83ha
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
EX-4.5
uoqesdwu
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.4
u1zagm lyq
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-1.2
8y14nuf
7 Nov 23
Automatic shelf registration
5:24pm
8-K
EX-99.1
mwhz003yh
8 Aug 23
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.1
amt5ton1qofeqy
5 May 23
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:30am
8-K
EX-1.1
vim97o0
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-10.1
1folao27e5ldv88
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
5ds2ej
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am